Table 3.

Univariate survival analysis for locoregional control, distant metastasis-free rate, and overall survival (significant values bolded)

	Locoregional control p (2y estimate/HR)	Distant metastasis-free p (2y estimate/HR)	Overall survival p (2y estimate/HR)
Age (continuous)	0.949	0.024 (HR 1.018)	0.003 (HR 1.017)
Gender	0.363	0.203	0.908
Race	0.986	0.144	0.144
BMI (continuous)	0.149	0.545	0.753
Comorbidities
Diabetes	0.570	0.759	0.122
Coronary artery disease	0.762	0.203	0.236
Hyperlipidemia	0.361	0.556	0.579
Hypertension	0.621	0.300	0.726
Medications
Metformin	0.501	0.644	0.473
Pancreatic enzymes	0.525	0.050 (17.9 vs. 27.9%)	0.001 (26.2 vs. 46.2%)
Sulfonylurea	0.549	0.518	0.978
Insulin	0.308	0.592	0.030 (31.2 vs. 39.0%)
Statin (active use during treatment)	0.269 (28.9 vs. 10.9%)	0.882 (23.2 vs. 24.0%)	0.030 (34.1 vs. 39.4%)
Statin (before or at diagnosis)	0.559 (26.3 vs. 24.0%)	0.107 (21.2 vs. 35.0%)	0.021 (34.0 vs. 41.1%)
Glucocorticoid	0.160	0.449	0.139
Beta-blocker (before or at diagnosis)	0.043 (27.8 vs. 0.0%)	0.615	0.288
Beta-blocker (active use)	0.142 (23.6 vs. 33.3%)	0.662	0.206
Lymph node status	0.209	0.577	0.915
Resectability
Unresectable	0.034 (20.8%)	<0.001 (6.4%)	<0.001 (16.2%)
Borderline resectable	0.034 (11.1%)	<0.001 (23.1%)	<0.001 (42.5%)
Resectable	0.034 (40.4%)	<0.001 (36.4%)	<0.001 (58.8%)
Surgery	0.030 (13.2 vs. 47.1%)	<0.001 (5.2 vs. 37.1%)	<0.001 (15.0 vs. 61.3%)
Chemotherapy	0.617	0.003 (0.0 vs. 24.4%)	<0.001 (9.8 vs. 41.3%)
Immunotherapy	0.212	0.115	0.012 (33.5 vs. 91.7%)